Home Immunotherapy PharmaWatch: NeoTX & AstraZeneca (MedImmune) Enter into Immuno-Oncology Clinical Trial Collaboration

PharmaWatch: NeoTX & AstraZeneca (MedImmune) Enter into Immuno-Oncology Clinical Trial Collaboration

162
0
Immuno-oncology

NeoTX Therapeutics has entered into a clinical collaboration with MedImmune (AstraZeneca’s biologics research and development arm) for phase Ib/II studies investigating NeoTX’s naptumomab estafenatox in combination with IMNINZI (durvalumab).  Expected to start in 2019, naptumomab is a leading drug in NeoTX’s novel selective T cell Redirection (STR) platform.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.